Formulations containing hyaluronic acid

Details Formulations containing hyaluronic acid Formulations containing hyaluronic acid

1994-12-01

2000-09-05

Peselev, Elli

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 62, 536 551, A61K 3170

Patent

active

061143146

ABSTRACT:
Topically applied transdermally quick penetrating (best targeting the epidermis and subsequently remaining there for a prolonged period of time) systemic independent acting, combinations and formulations which employ, combine, or incorporate a therapeutically effective non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis together with an amount of hyaluronic acid and/or salts thereof (for example the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub units of hyaluronic acid to treat a disease and condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women and remain in the skin for a prolonged period of time.

REFERENCES:
patent: 4141973 (1979-02-01), Balazs
patent: 4303676 (1981-12-01), Balazs
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4684627 (1987-08-01), LeVeen et al.
patent: 4711780 (1987-12-01), Fahim
patent: 4725585 (1988-02-01), Wenge et al.
patent: 4736024 (1988-04-01), Della Valle et al.
patent: 4755544 (1988-07-01), Makino et al.
patent: 4795741 (1989-01-01), Leshchiner et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4814176 (1989-03-01), Makino et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 4946870 (1990-08-01), Partain, III et al.
patent: 4957744 (1990-09-01), della Valle et al.
patent: 4965353 (1990-10-01), della Valle et al.
patent: 4970298 (1990-11-01), Silver et al.
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5166331 (1992-11-01), Fidia
patent: 5639738 (1997-06-01), Falk et al.
Sandra Blakeslee, "Solid cores of tumors keeping out best drugs", Jul. 8, 1989 edition of the Globe and Mail, Toronto, Ontario p. D4.
Pam Harrison, "Toxic drug tamed but still potent" Ontario Medicine, vol. 8, No. 16 dated Aug. 21, 1989, Page 1.
The Merck Index Eleventh Edition, Centennial Edition, Hyaluronic Acid formulation, pp. 751 and 752.
Alan R. Liss, Inc., Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists, Immunity to Cancer II.
Goodwin, J.S. Prostaglandin E and Cancer Growth Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, Augmentive Agents in Cancer Therapy, Raven Press, New York, (1981).
Dr. Samuel Asculai, "Inactivation of Herpes Simplex Viruses by Nonionic Surfactants ", Antimicrobial Agents and Chemotherapy, Apr. 1978, pp. 686-690.
Chemical Abstracts, vol. 76, No. 10; W. E. Sneader; "Possible Mechanism for action of DMSO on Percutaneous absorption", J. Pharm. Pharmcol, 1971, 23 (Supp).

Affiliated with

Also associated with

Rating

Formulations containing hyaluronic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulations containing hyaluronic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations containing hyaluronic acid will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2212261